Identifying blood biomarkers for type 2 diabetes subtyping: a report from the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial
Authors' conclusion
We identified 25 serum biomarkers, as independent determinants of type 2 diabetes subtypes, that could be combined into a diagnostic test for subtyping.
Study context
- Population
- ORIGIN trial participants with diabetes categorised into five subtypes using five clinical variables; 233 cardiometabolic protein biomarkers assessed
- Participants
- 7,017 participants
- Comparison
- Circulating protein biomarkers to distinguish each diabetes subtype vs the others
- Severe autoimmune diabetes (SAID)n = 241
- Severe insulin-deficient diabetes (SIDD)n = 1,594
- Severe insulin-resistant diabetes (SIRD)n = 914
- MODn = 1,595
- Mild age-related diabetes (MARD)n = 2,673
Methodological detailsbiomarker study, forward-selection logistic regression
- Biomarker study
- Forward-selection logistic regression
Primary result
As reported in the abstract
Biomarkers independently determining each subtype vs the others; AUC ROC of biomarker sets (1 to 25 biomarkers)
| Group | Value | AUC ROC range |
|---|---|---|
| SIDD | 13 biomarkers | 0.611 to 0.734 |
| SIRD | 2 biomarkers | 0.723 to 0.861 |
| MOD | 7 biomarkers | 0.672 to 0.742 |
| MARD | 11 biomarkers | 0.651 to 0.751 |
Value
SIDD13 biomarkers
SIRD2 biomarkers
MOD7 biomarkers
MARD11 biomarkers
AUC ROC range
SIDD0.611 to 0.734
SIRD0.723 to 0.861
MOD0.672 to 0.742
MARD0.651 to 0.751
- Biomarkers that were independent determinants of subtypes (all p<4.3 × 10-5)
- 25
Original publication
Identifying blood biomarkers for type 2 diabetes subtyping: a report from the ORIGIN trial. Diabetologia. Published 1 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →